Ramja Genosensor
Prathamasense: Diagnostic Device for Microbial Infection and Antimicrobial Resistance
POTENTIAL IMPACT
50
Kits and 20 devices to be deployed in healthcare facilities
1000+
blood and urine samples to be examined
Geographical Focus
- Pan India
PoojaFounder & Director, Ramja Genosensor
With SAMRIDH’s backing, Ramja Genosensor is poised to expedite research and development endeavors, tackling healthcare challenges such as infection and AMR, and leaving a profound mark on the global healthcare and diagnostics sector. This partnership is helping us not only build the company’s credibility but also pave the way for our international expansion.
Samridh support
SAMRIDH is providing financial assistance to Ramja Genosensor to scale the production and distribution capacity of the PRATHMASENSE device and kit, conduct crucial clinical trials in hospitals, and administer research and development for product upgradation. The collaboration aims to deploy 50 kits and 20 devices at health facilities across India, with a focus on tier II and III cities. Additionally, the support aims to strengthen marketing and sales plans for the solution, targeting both B2B (business-to-business) and B2G (business-to-government) markets through distributor partnerships, informative webinars, and influencer marketing. This multi-pronged approach ensures widespread access and adoption of this potentially life-saving technology.
1.2 Million people died from antibiotic-resistant bacterial infections in 2019, globally.[1]
10 Million people are estimated to lose their lives by 2050, due to antimicrobial resistance (AMR).[2]
24 Million people can be pushed into extreme poverty by 2030, due to AMR.[3]
Globally, Antimicrobial Resistance (AMR) poses a significant challenge in healthcare, impacting treatment effectiveness and straining healthcare systems. Timely infection detection, especially in ICUs, is vital. However, traditional diagnostic methods like cultures are slow, taking 2-5 days for results, leading to delayed antibiotic prescription. Despite guidelines advocating for 100% baseline culture investigation in ICUs, immediate results are unavailable, exacerbating AMR. Overuse and misuse of antibiotics contribute to drug-resistant infections, emphasizing the critical need for swift diagnosis to prevent further escalation of AMR-related challenges and safeguard patient well-being.
Ramja Genosensor’s PRATHMASENSE is a rapid, user-friendly, and cost-efficient solution for detecting microbial infections and antimicrobial susceptibility/resistance in less than 2 hours. Utilizing an electrochemical DNA biosensor, this innovative device identifies gene-specific bacteria via a redox reaction on the screen-printed electrode. Through microfabrication-based technology, this genotypic test swiftly detects infection-causing bacteria and superbug resistance, capable of isolating genomic DNA from diverse samples, including 1 ml of blood, urine, or any biological fluid. Ramja Genosensor aims to reduce deaths from delayed diagnosis, minimize healthcare costs, and improve patient outcomes.
Key Stakeholders
